These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20824037)

  • 21. Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.
    Oliver RT
    Oncologist; 1996; 1(4):278-279. PubMed ID: 10388003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Are men and women with breast cancer treated equally in Germany?].
    Dippmann AK; Damrau C; Hengelbrock J; Albert US; Lebeau A; Lux MP; Veit C
    Z Evid Fortbild Qual Gesundhwes; 2020 Sep; 155():1-10. PubMed ID: 32861615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor content in malignant breast tumors in men--a review.
    Olsson H
    J Mammary Gland Biol Neoplasia; 2000 Jul; 5(3):283-7. PubMed ID: 14973390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone Therapy for Breast Cancer in Men.
    Khan MH; Allerton R; Pettit L
    Clin Breast Cancer; 2015 Aug; 15(4):245-50. PubMed ID: 26165199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.
    Xu L; Li JH; Ye JM; Duan XN; Cheng YJ; Xin L; Liu Q; Zhou B; Liu YH
    Chin Med J (Engl); 2017 Aug; 130(16):1945-1952. PubMed ID: 28776547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer.
    Kida K; Hess KR; Lim B; Iwase T; Chainitikun S; Valero V; Lucci A; Le-Petross HC; Woodward WA; Krishnamurthy S; Hortobagyi GN; Tripathy D; Ueno NT
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
    Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
    Popovska S; Ivanov I
    Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
    Alvarez-Lopez I; Bezares S; Dalmau Portulas E; García-Martínez E; García-Sáenz JÁ; Gil-Gil M; Martínez de Dueñas E; Ribelles N; Santaballa Bertrán A
    Clin Transl Oncol; 2020 Aug; 22(8):1364-1377. PubMed ID: 32052382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
    Shah AN; Metzger O; Bartlett CH; Liu Y; Huang X; Cristofanilli M
    Oncologist; 2020 Jun; 25(6):e900-e908. PubMed ID: 32176406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of anatomic and prognostic stages of breast cancer according to the 8th edition of the TNM staging system - Retrospective analysis based on data from deceased patients once diagnosed with breast cancer].
    Zombori T; Lehóczky L; Cserni B; Nyári T; Cserni G
    Orv Hetil; 2017 Sep; 158(35):1373-1381. PubMed ID: 28847177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
    Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
    Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.
    Chavez-MacGregor M; Mittendorf EA; Clarke CA; Lichtensztajn DY; Hunt KK; Giordano SH
    Oncologist; 2017 Nov; 22(11):1292-1300. PubMed ID: 28592619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.